Hepatocyte Growth Factor and Cardiovascular Autonomic Function
NCT00478127 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2007-05-24
Summary
In this study, we tested the hypothesis that elevated HGF is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.
Conditions
- Type-2 Diabetes
Sponsors & Collaborators
-
Oita Red Cross Hospital
lead OTHER
Principal Investigators
-
Futoshi Anan · Oita Red Cross Hospital
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445 ·Status: COMPLETED ·Phase: NA
-
Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease
NCT01879293 ·Status: COMPLETED ·Phase: PHASE4
-
Glucagon Resistance in Patients With NAFLD
NCT04042142 ·Status: COMPLETED ·Phase: NA
-
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
NCT05093517 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes
NCT01492283 ·Status: COMPLETED
-
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
NCT00191282 ·Status: COMPLETED ·Phase: PHASE4
-
Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia
NCT02337660 ·Status: COMPLETED ·Phase: NA
-
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging
NCT04352738 ·Status: COMPLETED
-
Studies of Insulin and Glucagon Action in the Liver
NCT07300982 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)
NCT01573949 ·Status: COMPLETED ·Phase: NA
-
Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure
NCT02810132 ·Status: COMPLETED ·Phase: PHASE2
-
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
NCT02833415 ·Status: COMPLETED ·Phase: PHASE4
-
Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition
NCT03533179 ·Status: COMPLETED ·Phase: PHASE4
-
Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis
NCT04907721 ·Status: COMPLETED ·Phase: NA
-
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
NCT00118937 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Ghrelin on Sympathetic Nervous System
NCT00912587 ·Status: COMPLETED ·Phase: NA
-
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
NCT03560323 ·Status: COMPLETED ·Phase: PHASE1
-
Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus
NCT01689051 ·Status: COMPLETED ·Phase: NA
-
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
NCT04135287 ·Status: UNKNOWN ·Phase: PHASE4
-
Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes
NCT04733508 ·Status: UNKNOWN ·Phase: NA
-
Characterization of Beta Cell Failure
NCT00869102 ·Status: WITHDRAWN ·Phase: NA
-
Glucagon Modulation of Ghrelin Secretion
NCT00929812 ·Status: UNKNOWN ·Phase: PHASE3
-
B-type Natriuretic Peptide and Glucose Metabolism
NCT01324739 ·Status: COMPLETED ·Phase: NA
-
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
NCT05597202 ·Status: UNKNOWN ·Phase: PHASE4
-
Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect
NCT00784745 ·Status: COMPLETED ·Phase: NA